JP2019531704A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531704A5
JP2019531704A5 JP2019504812A JP2019504812A JP2019531704A5 JP 2019531704 A5 JP2019531704 A5 JP 2019531704A5 JP 2019504812 A JP2019504812 A JP 2019504812A JP 2019504812 A JP2019504812 A JP 2019504812A JP 2019531704 A5 JP2019531704 A5 JP 2019531704A5
Authority
JP
Japan
Prior art keywords
peptide
immunomodulatory polypeptide
binding peptide
binding
subunit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019504812A
Other languages
English (en)
Japanese (ja)
Other versions
JP7295795B2 (ja
JP2019531704A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/044549 external-priority patent/WO2018023093A1/en
Publication of JP2019531704A publication Critical patent/JP2019531704A/ja
Publication of JP2019531704A5 publication Critical patent/JP2019531704A5/ja
Priority to JP2023024001A priority Critical patent/JP2023062104A/ja
Application granted granted Critical
Publication of JP7295795B2 publication Critical patent/JP7295795B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019504812A 2016-07-29 2017-07-28 免疫調節ポリペプチドならびに関連する組成物および方法 Active JP7295795B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023024001A JP2023062104A (ja) 2016-07-29 2023-02-20 免疫調節ポリペプチドならびに関連する組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662369017P 2016-07-29 2016-07-29
US62/369,017 2016-07-29
PCT/US2017/044549 WO2018023093A1 (en) 2016-07-29 2017-07-28 Immunomodulatory polypeptides and related compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023024001A Division JP2023062104A (ja) 2016-07-29 2023-02-20 免疫調節ポリペプチドならびに関連する組成物および方法

Publications (3)

Publication Number Publication Date
JP2019531704A JP2019531704A (ja) 2019-11-07
JP2019531704A5 true JP2019531704A5 (https=) 2020-09-03
JP7295795B2 JP7295795B2 (ja) 2023-06-21

Family

ID=59631857

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019504812A Active JP7295795B2 (ja) 2016-07-29 2017-07-28 免疫調節ポリペプチドならびに関連する組成物および方法
JP2023024001A Pending JP2023062104A (ja) 2016-07-29 2023-02-20 免疫調節ポリペプチドならびに関連する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023024001A Pending JP2023062104A (ja) 2016-07-29 2023-02-20 免疫調節ポリペプチドならびに関連する組成物および方法

Country Status (10)

Country Link
US (1) US12304935B2 (https=)
EP (1) EP3490585B1 (https=)
JP (2) JP7295795B2 (https=)
CN (1) CN110087672A (https=)
AU (1) AU2017301880C1 (https=)
CA (1) CA3031955A1 (https=)
ES (1) ES2951552T3 (https=)
MA (1) MA45779A (https=)
MX (1) MX2019001185A (https=)
WO (1) WO2018023093A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
MA45779A (fr) 2016-07-29 2019-06-05 Juno Therapeutics Inc Polypeptides immunomdulateurs et compositions et procédés associés
US20210017247A1 (en) 2017-07-03 2021-01-21 Torque Therapeutics, Inc. Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
WO2019178078A1 (en) 2018-03-14 2019-09-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy
SG11202008926RA (en) * 2018-03-14 2020-10-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy
CA3100005A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
US11319380B2 (en) 2018-06-04 2022-05-03 Precigen, Inc. MUC16 specific chimeric antigen receptors and uses thereof
CN109306016B (zh) * 2018-08-15 2021-10-22 华东师范大学 共表达细胞因子il-7的nkg2d-car-t细胞及其用途
AU2019336229A1 (en) * 2018-09-07 2021-03-18 Sotio, LLC Chimeric receptor polypeptides in combination with trans metabolism molecules modulating intracellular lactate concentrations and therapeutic uses thereof
WO2020181983A1 (zh) * 2019-03-12 2020-09-17 重庆精准生物技术有限公司 缺氧调控启动子及其应用
CN111848811B (zh) * 2019-04-27 2024-10-01 张晋宇 一种蛋白质异二聚体及其用途
EP3969119A1 (en) 2019-05-17 2022-03-23 Xencor, Inc. Il-7-fc-fusi0n proteins
CN112294760B (zh) * 2019-07-26 2025-12-12 宁波新致生物科技有限公司 一种液体制剂及其应用
US20230312685A1 (en) * 2019-10-25 2023-10-05 Mayo Foundation For Medical Education And Research Bi-Peptide with Affinity to Extracellular Matrix Proteins or Cells and to Growth Factors for Tissue Healing and Regeneration
KR20220109436A (ko) 2019-12-03 2022-08-04 에보텍 인터내셔널 게엠베하 인터페론-결합된 항원 결합 단백질 및 이의 용도
WO2021115333A1 (zh) * 2019-12-10 2021-06-17 苏州克睿基因生物科技有限公司 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
CN111153961B (zh) * 2020-01-08 2022-02-18 郑州大学 一种亲和pd-1的肽及其应用
JP2023511717A (ja) * 2020-01-30 2023-03-22 パーデュー・リサーチ・ファウンデーション 治療用タンパク質のリガンド媒介性送達およびその使用
CN111533785B (zh) * 2020-02-11 2022-03-08 北京市肿瘤防治研究所 靶向免疫检查点tim3结合肽及其应用
US12508309B2 (en) * 2020-02-18 2025-12-30 Vacdiagn Biotechnology Co., Ltd. Recombinant viral vector, immunogenic composition comprising same, and uses
CN115698268A (zh) * 2020-05-04 2023-02-03 萨利欧基因治疗公司 基于转座的疗法
CN112063588A (zh) * 2020-08-13 2020-12-11 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CN116724046A (zh) * 2020-09-17 2023-09-08 欧萨尔普罗席纳有限公司 用于治疗阿尔茨海默病之β淀粉样蛋白疫苗
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
CN114907485B (zh) * 2021-02-08 2024-04-26 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN115029317B (zh) * 2021-02-23 2025-10-28 赛浦生物科技(长春)有限公司 用于过敏性鼻炎的鼻喷雾剂及制备方法
TW202321282A (zh) 2021-07-19 2023-06-01 美商再生元醫藥公司 Il12受體促效劑及其使用方法
WO2023015822A1 (zh) * 2021-08-13 2023-02-16 上海鑫湾生物科技有限公司 缺氧触发的人工转录因子、转录控制系统及其应用
WO2023060047A1 (en) * 2021-10-04 2023-04-13 California Institute Of Technology Thermal state switches in macrophages
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2023137069A2 (en) * 2022-01-12 2023-07-20 St. Jude Children's Research Hospital, Inc. Bispecific chimeric antigen receptors targeting grp78 and cd123 or grp78 and b7h3
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
US20250243279A1 (en) 2023-10-17 2025-07-31 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b
WO2025129120A2 (en) * 2023-12-15 2025-06-19 Port Therapeutics, Inc. Use of thermal bioswitches for treating autoimmune diseases
CN117986386B (zh) * 2024-02-06 2024-11-29 康立泰生物医药(青岛)有限公司 重组人白细胞介素-35及其制备方法和应用
WO2025176860A1 (en) 2024-02-23 2025-08-28 Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts Dual chimeric antigen receptor construct targeting cea and epcam

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (https=) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US6653105B2 (en) 1998-02-11 2003-11-25 Vitagen, Inc. Clonal cells and cell lines derived from C3A cells and methods of making and using them
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
JP4793971B2 (ja) * 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
AU3958101A (en) 2000-03-15 2001-09-24 Univ Pohang Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant
EP1268795A2 (en) 2000-03-24 2003-01-02 Bayer Aktiengesellschaft Regulation of human mas oncogene-related g protein-coupled receptor
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1418184A1 (en) 2002-11-08 2004-05-12 Cell Center Cologne GmbH Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
GB0228465D0 (en) 2002-12-06 2003-01-08 Univ Belfast A method of treating disease
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
ATE459648T1 (de) 2005-05-11 2010-03-15 Philogen Spa Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12
BRPI0620648B1 (pt) * 2005-12-30 2022-12-20 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
WO2007084364A2 (en) 2006-01-13 2007-07-26 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Improved il-12 for expression in mammalian cells
US8188220B2 (en) 2006-12-06 2012-05-29 Sanford-Burnham Medical Research Institute Methods and compositions related to targeting wounds, regenerating tissue, and tumors
US8536113B2 (en) * 2006-12-21 2013-09-17 Janssen Biotech, Inc. EGFR binding peptides and uses thereof
CA2682527C (en) 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
EP2150618B1 (en) 2007-05-04 2017-10-11 University Health Network Il-12 immunotherapy for cancer
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
US8715964B2 (en) 2008-05-11 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Expression of IL-12 family heterodimers
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
AU2010241864B2 (en) 2009-04-30 2014-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
US8617557B2 (en) * 2010-03-12 2013-12-31 The Regents Of The University Of California Antibody fusion with IL-12 proteins with disrupted heparin-binding activity
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
KR20140033029A (ko) 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
EP2736535B1 (en) 2011-07-27 2018-10-17 Philogen S.p.A. Il-12 immunoconjugate
EP3692794A1 (en) 2011-09-16 2020-08-12 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
KR102134932B1 (ko) 2011-11-11 2020-07-17 프레드 헛친슨 켄서 리서치 센터 암을 위한 사이클린 a1―표적화된 t―세포 면역요법
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
SG10201609210SA (en) 2012-05-03 2016-12-29 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
DE112012007250B4 (de) 2012-12-20 2024-10-24 Mitsubishi Electric Corp. Fahrzeuginterne Vorrichtung und Programm
PT2961831T (pt) 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
WO2014139468A1 (en) 2013-03-15 2014-09-18 Admark Healthcare, Llc Fusion protein molecules and method of use
US10260038B2 (en) * 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
MA45779A (fr) 2016-07-29 2019-06-05 Juno Therapeutics Inc Polypeptides immunomdulateurs et compositions et procédés associés

Similar Documents

Publication Publication Date Title
JP2019531704A5 (https=)
CN111787951B (zh) 影响IgM血清半衰期的IgM Fc和J链突变
CN110536900B (zh) 调节补体依赖性细胞溶解效应子功能的修饰的人igm恒定区
CN115057936B (zh) 异源二聚体多特异性抗体形式
ES2732907T3 (es) Procedimiento de expresión
JP5738294B2 (ja) 抗vegfモノクローナル抗体およびその抗体を含む薬学的組成物
JP2024073531A5 (https=)
JP2012515556A5 (https=)
CN111423512B (zh) 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
FI3461261T3 (fi) Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja
RU2015144098A (ru) Четырехвалентные биспецифические антитела
WO2022116480A1 (zh) 含有肿瘤相关抗原taa抗体的三功能融合蛋白及其应用
JP2019528683A (ja) 多量体gitr結合分子及びその使用
JP2020505919A5 (https=)
CN105194661A (zh) 时空可调性抑制病理性靶细胞的系统
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
JP2023159379A (ja) Pd-1とvegfを標的とした四価二重特異性抗体、その製造方法および用途
JP2024507693A (ja) 二重特異性抗体
CN116284405B (zh) 靶向cd150蛋白的纳米抗体及其应用
CN113490690A (zh) 异源二聚体融合蛋白
JPWO2022133169A5 (https=)
CN117304319A (zh) 靶向人clec12b蛋白的纳米抗体及其应用
JPWO2020071554A5 (https=)
KR20220016152A (ko) 항-gal9 결합분자 활성화
CN117304320A (zh) 靶向小鼠clec12b蛋白的纳米抗体及其应用